GSA Capital Partners’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

GSA Capital Partners’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,075	Closed	-$408K	–	2027
2022 Q4	$408K	Sell	2,075 -2,247	-52%	-$482K	0.05%	729
2022 Q3	$972K	Sell	4,322 -544	-11%	-$110K	0.13%	174
2022 Q2	$616K	Buy	+4,866	New	+$559K	0.09%	373
2021 Q2	–	Sell	-3,299	Closed	-$397K	–	1670
2021 Q1	$397K	Buy	3,299 +14	+0.4%	+$1.59K	0.07%	477
2020 Q4	$334K	Buy	+3,285	New	+$304K	0.05%	681
2019 Q3	–	Sell	-31,000	Closed	-$621K	–	1778
2019 Q2	$621K	Buy	+31,000	New	+$621K	0.07%	530

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's KRTX Position: Q1 2023 in Review

GSA Capital Partners sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2023, closing a stake of 2,075 shares — an estimated $408K sold.

GSA Capital Partners first reported a position in KRTX in Q2 2019 and held it in 6 quarters. The position peaked at $972K in Q3 2022. 246 funds tracked by Wall St. Rank hold KRTX as of Q1 2023.

GSA Capital Partners reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
GSA Capital Partners sold 2,075 Karuna Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $408K.
GSA Capital Partners first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
GSA Capital Partners's Karuna Therapeutics, Inc. Common Stock position peaked at $972K in Q3 2022.
246 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2023.

Based on GSA Capital Partners's 13F filing for Q1 2023, filed 12 May 2023.